Alpha-1A Adrenergic Receptor Agonists for Right Ventricular Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective pharmacologic treatments for right ventricular failure (RVF), which is a serious condition associated with poor prognosis and involves impaired mitochondrial function and increased production of reactive oxygen species, leading to contractile dysfunction.
Innovation Solution
Development of α1A-AR agonist compounds and pharmaceutical compositions that modulate α1A-adrenergic receptor signaling to protect mitochondria and improve cardiac function, including compounds with specific structural formulas and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacologic treatments are used for right ventricular failure, then standard heart failure management is provided, but no effective treatment is available due to lack of targeted therapy
Solution Approach 1:
The patent applies parameter changes by developing novel α1A-AR agonist compounds with specific molecular structures (formulas 1 and 2 with various substituents R1-R5b) that differ from conventional heart failure medications. These compounds represent a new pharmacological parameter space targeting the alpha-1A adrenergic receptor specifically, which has not been effectively exploited in RVF treatment before.
Solution Approach 2:
The patent uses α1A-AR agonist compounds as intermediary substances that mediate between the administered drug and the mitochondrial protective effect. These compounds act as intermediaries that specifically bind to and activate alpha-1A adrenergic receptors on cardiomyocytes, triggering downstream signaling pathways that protect mitochondria and reduce ROS, thereby translating pharmacological intervention into therapeutic effect.
2Reliability
If mitochondrial function is impaired in RVF, then contractile dysfunction occurs, but no therapy specifically addresses mitochondrial protection
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the harmful overactive mitochondrial respiration and ROS production into a beneficial state. The α1A-AR agonist compounds selectively modulate mitochondrial function to reduce pathogenic ROS production while maintaining or improving ATP production, effectively transforming the harmful mitochondrial hyperactivity into a protective state that supports cardiac function.
Solution Approach 2:
The patent changes the functional parameters of mitochondria by administering α1A-AR agonists that specifically alter mitochondrial membrane potential, respiratory chain activity, and ROS generation rates. These parameter changes shift mitochondrial function from a harmful state (high ROS, impaired bioenergetics) to a beneficial state (reduced ROS, improved ATP production), directly addressing the root cause of RVF.
3Reliability
If α1A-AR agonist compounds are developed, then specific mitochondrial protection is achieved, but new compound development is required
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into distinct structural components and substituents (R1, R2, R3a, R3b, R4, R5a, R5b) that can be independently varied. This modular structure allows systematic optimization of each component's contribution to α1A-AR binding affinity and mitochondrial protective activity, simplifying the drug development process through structure-activity relationship analysis.
Solution Approach 2:
The patent achieves universality by designing α1A-AR agonist compounds that simultaneously perform multiple functions: (1) binding to and activating alpha-1A adrenergic receptors, (2) protecting mitochondrial membranes from oxidative damage, (3) reducing ROS production, and (4) improving cardiac contractile function. This multi-functionality is encoded in the core molecular structure with its specific substituents, allowing a single compound class to address multiple aspects of RVF pathology.
Data Source
AI summary
The present disclosure relates to α1A-AR agonist compounds, pharmaceutical compositions, and methods of using the compounds and composition for treating conditions associated with right ventricular failure. In addition the disclosed compounds and compositions can be used for treating cardiomyopathies, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, restrictive cardiomyopathy, left ventricular noncompaction, right ventricular failure (RVF), and takotsubo cardiomyopathy. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.